Mayo Clinic and Thermo Fisher Scientific are working together to evaluate next-generation sequencing, mass spectrometry and immunology diagnostic tools for multiple applications, including myeloid leukemia and therapeutic drug monitoring panels to deliver access to more precise and personalized insights for patient care.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
